CD274 and neoplasm: A novel CD16/PD-L1 dual-targeting aptamer named CP-bi-apt was developed, which integrates the functions of immune checkpoint blockade and the recruitment of NK cells to directly contact with tumor cells, thus enhancing antitumor immunity.